GlobeNewsWire
26 May 2026, 20:53 UTC · 2h ago
Source · https://www.globenewswire.com/news-release/2026/05/26/3301508/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Regeneron-Pharmaceuticals-Inc-REGN.html
Read source
Search tags
Story key points
2 claims · impact-rated
Regeneron's Phase 3 trial for fianlimab combined with cemiplimab failed to reach statistical significance for the primary endpoint of progression-free survival in metastatic melanoma. — Clinical trial failures for primary endpoints typically lead to significant valuation drops and loss of future revenue potential for the drug candidate.
-0.70Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Regeneron and its officers following the trial results. — The launch of a legal investigation into securities fraud introduces regulatory risk and potential future litigation costs for the company.
-0.40Impact vectors
5 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
Ticker attribution
Model heads
The company faces a class action investigation for potential securities fraud following a failed Phase 3 clinical trial and a significant stock price drop.
The company is the subject of an investigation by a law firm on behalf of investors.
The company is the subject of an investigation by a law firm on behalf of investors.
No ticker relationship head found.
